Big Pharma looks to capitalize on success of vitamin D by turning it into a ‘drug’ for kidney disease

Natural News | July 31, 2011

By Jonathan Benson

With an incredible success rate for vitamin D in treating a myriad of health conditions, it is no wonder that some drug companies are looking for new ways to capitalize on this natural, inexpensive nutrient.

Biopharmaceutical giant Rockwell Medical recently announced that it has acquired a US Food and Drug Administration (FDA) Abbreviated New Drug Application (ANDA) for a generic, injectable form of vitamin D called Calcitriol, that it openly refers to as a “drug.”

Marketed under several brand names including Rocaltrol (Roche), Calcijex (Abbott), and Decostriol (Mibe, Jesalis), Calcitriol is really nothing more than vitamin D3, or 1,25-dihydroxycholecalciferol, that has been placed in a syringe with sterile fluids and other additives. And yet Rockwell Medical, as well as various medical information sources, refer to Calicitriol as a “drug,” which is why Rockwell Medical obtained an ANDA in the first place.

Be the first to comment on "Big Pharma looks to capitalize on success of vitamin D by turning it into a ‘drug’ for kidney disease"

Leave a Reply